How do you manage endocrine therapy for premenopausal women with breast cancer who are heterozygous for factor V Leiden but have no history of thrombosis?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UPMC • Hematology • NCI-CCC Breast Tumor Board Question • Benign Hematology • Breast Cancer, Non-metastatic

Answer from: Medical Oncologist at Community Practice

This is a difficult situation given that the literature is contradictory on this topic. Both tamoxifen and a factor V Leiden mutation independently increase risk of thromboembolic events. It is unclear whether, together, they would be additive in conferring risk of thrombosis. Dr. Cuzick wrote a ve...

Related Questions